ArticleEClinicalMedicine2025
Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04195828 (Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of immune checkpoint inhibitors as neoadjuvant/perioperative therapy for locally advanced resectable gastric/gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Arise-FJ-G005 study compared the efficacy and safety of perioperative camrelizumab and apatinib combined with chemotherapy with those of perioperative chemotherapy alone for locally advanced gastric cancer (LAGC) and assessed its effect on major pathological response (MPR). Herein, we report the 3-year survival outcomes of this trial. Methods: Arise-FJ-G005 was a multicenter, open-label, phase 2, randomized controlled trial (NCT04195828), conducted between June 2020 and March 2022. Patients with LAGC (clinical T2-4, N+, M0) were randomly assigned to receive perioperative CA-SAP (camrelizumab and apatinib combined with nab-paclitaxel plus S-1 [SAP]) or SAP alone for three cycles preoperatively and five cycles postoperatively. The primary endpoint was the MPR. This report focuses on the secondary endpoints of 3-year progression-free survival (PFS) and overall survival (OS). Findings: Between June 18, 2020, and March 31, 2022, 106 patients were randomly assigned to the CA-SAP or the SAP group in a 1:1 ratio, of whom 51 in the CA-SAP and 53 in the SAP group were included in the modified intention-to-treat analysis. The 3-year PFS was 64% (95% confidence [CI]: 52%-79%) and 48% (95% CI: 36%-64%) in the CA-SAP and SAP groups, respectively, with an adjusted hazard ratio (HR) of 0.512 (95% CI: 0.263-0.998). The 3-year OS was 63% (95% CI: 51%-78%) and 61% (95% CI: 49%-77%) in the CA-SAP and SAP groups, respectively (adjusted HR: 0.987, 95% CI: 0.481-2.026). Exploratory analysis revealed heterogeneity in the treatment effect among subgroups according to performance status. Interpretation: Adding camrelizumab and apatinib to perioperative chemotherapy did not result in a meaningful improvement in the 3-year OS of unselected patients with LAGC. Due to its suboptimal tolerability and effectiveness, future research should focus on identifying subpopulations that may benefit from this combination treatment strategy. Funding: Construction Funds for "High-level Hospitals and Clinical Specialties" of Fujian Province (No. [2021]76).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.